[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-depressive-episode\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-depressive-episode":493},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,49,71,98,124,155,180,207,233,258,286,310,333,359,388,417,450,474],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100601507",false,"NCT07111390","Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)","A Feasibility Pilot Study of Home-Based Intermittent 60Hz Light Therapy for the Treatment of Depression","Inclusion Criteria:\n\n* Age between 24 and 65 years (inclusive)\\*.\n* Confirmed diagnosis of Major Depressive Disorder (MDD), based on MINI interview.\n* Hamilton Depression Rating Scale (HDRS-17) score ≥17 at screening.\n* On a stable dose of antidepressant medication for at least 30 days prior to HDRS-17 screening.\n* No evidence of premorbid cognitive impairment, as demonstrated by a standard score \\>85 on the WRAT-5 Reading Recognition Subtest.\n* Confirmed access to a local provider that has primary responsibility for the subjects' clinical care, and who is available for contact in case of increased subject risk due to depressive symptoms.\n* Able to provide informed consent and comply with study procedures.\n* Access to a quiet space suitable for home-based light stimulation sessions.\n* English speaking: All study materials and assessments are only validated in English\n\nExclusion Criteria:\n\n* Presence of primary neurological or autoimmune disorders.\n* Presence of psychiatric comorbidities as determined by the MINI interview (e.g., anxiety disorders, OCD, PTSD, bipolar disorder, psychotic disorder).\n* Current or recent diagnosis of alcohol or substance use disorder.\n* History of bipolar disorder or any psychotic disorder.\n* Clinically significant suicidal ideation or behavior, based on clinician judgment and the Columbia-Suicide Severity Rating Scale (C-SSRS).\n* History of seizure disorder or epilepsy.\n* History of migraine, tinnitus, or photosensitivity.\n* Diagnosis of retinal disease, cataract, or other visual impairments that may interfere with light exposure.\n* Regular use of anti-inflammatory drugs or anticoagulants (e.g., clopidogrel).\n* Pregnancy and Breastfeeding: Currently pregnant, planning pregnancy during the study period, or breastfeeding","ALL","24 Years","65 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot study evaluates the feasibility, safety, and preliminary efficacy of home-based 60Hz intermittent light therapy in adults with a major depressive episode (MDE). Participants will be randomized in a 2:1 ratio to receive either active or sham 60Hz intermittent light stimulation for 30 minutes daily (Monday through Friday) over three weeks. The light is delivered through a wearable headset. Clinical assessments will be conducted remotely at baseline, mid-point, post-treatment, and follow-up to measure changes in depressive symptoms.",[26,27,28,29],"Depression","MDD","Major Depressive Disorder","Major Depressive Episode",[31,27,26,32,33,34,35],"Brain stimulation","Light therapy","Wearable","Neuromodulation","Telehealth","RECRUITING","2026-06-25",{"date":39,"type":40},"2026-06-29","ACTUAL",{"date":42,"type":40},"2025-08-18",{"date":44,"type":20},"2027-02-01",{"name":46,"class":47},"NYU Langone Health","OTHER",1,{"id":50,"slug":4,"hasResults":10,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100636964","NCT07572526","tDCS: Sleep to Mood in Depression (S2M-D)","Sleep Consolidation as a Mechanistic Pathway Linking Home-Based tDCS to Antidepressant Response (S2M-D)","Inclusion Criteria:\n\n1. Ability to read and understand study materials in English, as demonstrated by a standard score \\>85 on the WRAT-5 Reading Recognition Subtest\n2. MADRS-S ≥18 during screening\n3. Confirmed diagnosis of MDD, based on clinician interview\n4. If taking antidepressant medication, the dose must be stable for at least 30 days prior to pre-screening.\n5. Confirmed access to a local provider that has primary responsibility for the subjects' clinical care, and who is available for contact in case of increased subject risk due to depressive symptoms OR confirmed acknowledgement and identification of local resources.\n6. Able to provide informed consent and comply with study procedures.\n7. Access to a quiet space suitable for home-based tDCS stimulation sessions.\n\nExclusion Criteria:\n\n1. Current major medical condition that, in the opinion of the study clinician, would interfere with study participation, safety, or interpretation of study outcomes.\n2. Current or past bipolar disorder, psychotic disorder, or current (past 6 months) alcohol or substance use disorder, as determined by clinician assessment at screening.\n3. Clinically significant suicidal ideation or behavior, based on clinician assessment and the Columbia-Suicide Severity Rating Scale (C-SSRS).\n4. Use of prescription or over-the-counter sleep-promoting medications or initiation of behavioral interventions specifically targeting sleep in the past 30 days from pre-screening.\n5. History of seizure disorder or epilepsy.\n6. Presence of an active implanted medical device above the neck (e.g., deep brain stimulator, cochlear implant) or non-MRI-compatible metallic implants in the head or neck region.\n7. Current use of prescription or over-the-counter sleep medications, or active participation in any behavioral or pharmacologic treatment specifically targeting sleep.\n8. Pregnancy and Breastfeeding: Currently pregnant, planning pregnancy during the study period, or breastfeeding o If able to become pregnant, participants will be required to use medically accepted birth control methods, including hormonal methods (e.g., pills, patches, implants), barrier methods (e.g., condoms or diaphragm with spermicide), intrauterine device (IUD), or abstinence. Participants will be advised not to become pregnant during the study.","18 Years",{"count":57,"type":20},35,[23],"The purpose of this study is to determine whether changes in sleep consolidation occur during home-based transcranial direct current stimulation (tDCS) in adults with moderate depression and whether these changes are temporally associated with improvements in depressive symptoms.",[28,27,26,29],[27,31,26,62,34,33,35],"tDCS","2026-06-05",{"date":65,"type":40},"2026-06-08",{"date":67,"type":40},"2026-06-04",{"date":69,"type":20},"2027-12-31",{"name":46,"class":47},{"id":72,"slug":4,"hasResults":10,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":48},"100585433","NCT06902298","Personalized Ultrasonic Brain Stimulation for Depression (R61)","Personalized Ultrasonic Brain Stimulation for Depression: A Study of Target Engagement and Mood Effects","Inclusion Criteria:\n\n1. Age 18-65, any gender.\n2. Primary diagnosis of DMS-5 major depressive disorder (MINI).\n3. Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months (MINI).\n4. Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score \\> 10.\n5. History of at least 2 failed trials of evidence-based antidepressant medication and\u002For psychotherapy (at least one trial during the current depressive episode).\n6. Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study.\n7. For participants of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study.\n8. Capacity to provide informed consent; provision of a signed and dated consent form\n9. Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.\n10. Agrees to allow any and all forms of communication between the investigators\u002Fstudy staff and any healthcare provider who currently provides and\u002For has provided service to the patient\u002Fsubject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.\n11. Agrees to provide the name and verifiable contact information (email and mailing addresses, mobile and land-line phone numbers, as applicable) of at least two persons 22 years or older who reside within a 60-minute drive of the patient's residence. Subject agrees that in the event of a safety concern or event during study participation, research staff is at liberty to contact these individuals if the subject does not respond to contact attempts.\n\nExclusion Criteria:\n\n1. History of serious brain injury or other neurologic disorder.\n2. Poorly managed general medical condition.\n3. Pregnant or breast feeding.\n4. Implanted device in the head or neck.\n5. MRI intolerance or contraindication.\n6. Brain stimulation treatment such as ECT, TMS, or VNS (past month).\n7. Recent change in antidepressant treatments (past month).\n8. 8\\. Moderate-High Risk of Suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (answers YES to Question 3 and NO to Question 6 (Moderate risk) or YES to Question 4, 5, or 6 (High risk)) and\u002For in the clinical judgement of the PI or a study psychiatrist\n9. Suicidal behavior (past year).\n10. Serious suicide attempt 33 (lifetime).\n11. Moderate-to-severe substance use disorder (MINI, past 3 months).\n12. Obsessive compulsive disorder, primary diagnosis (MINI, past month).\n13. Posttraumatic stress disorder, primary diagnosis (MINI, past month).\n14. Bipolar-spectrum disorder (MINI, lifetime).\n15. Schizophrenia-spectrum disorder (MINI, lifetime).\n16. Neurocognitive disorder (DSM-5, past year).\n17. Severe personality disorder.\n18. Clinically inappropriate for participation in the study as determined by the study team.",{"count":78,"type":20},30,[80,81],"PHASE1","PHASE2","This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring. Individualized optimal targets will be selected using structural MRI and diffusion tractography. Brain target engagement will be evaluated using functional MRI.",[29,84,85],"Depression - Major Depressive Disorder","Treatment-Resistant Major Depressive Disorder",[87,88],"ultrasonic neuromodulation","low-intensity focused ultrasound","2026-04-29",{"date":91,"type":40},"2026-05-01",{"date":93,"type":40},"2025-03-10",{"date":95,"type":20},"2026-11",{"name":97,"class":47},"Brian Mickey",{"id":99,"slug":4,"hasResults":10,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":48},"100628515","NCT07462637","Signature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE)","SoLuRep","Patients :\n\nInclusion Criteria:\n\n1. Adults between 18 and 65 years old\n2. Patients with a diagnosis of MDE as part of a unipolar or bipolar disorder (DSM-5 TR criteria)\n3. Patients with a clinician-rated MADRS score ≥ 20 indicating a moderate to severe depressive symptoms with a prescription of LT for MDE treatment\n4. For patients with bipolar disorder type 1: With prophylactic mood stabilizer treatment at an effective dose (standardized and at a preventive dose for manic episode prevention) and stable for at least 4 weeks (background treatment for bipolar disorder): Lithium (Téralithe® LP 400 or 250) or Sodium Valproate (Dépakote® 500) or Atypical antipsychotics (also known as second-generation antipsychotics), defined as follows and dosed prior to inclusion in the month preceding:\n\n   * For Lithium, controlled by serum lithium level, \\>0.5 mEq\u002FL for Téralithe 250 and \\> 0.7 mEq\u002FL for Téralithe LP 400 ; for Sodium Valproate, controlled by serum sodium divalproate level \\>40mg\u002FL\n   * For antipsychotics, only the following molecules will be accepted at the indicated dosages, as they have marketing authorization in France as prophylactic mood stabilizers for manic episode prevention in bipolar disorder: Quétiapine (≥150-800mg), Aripiprazole (≥ 15-30mg), Olanzapine (≥ 10-20mg)\n5. Patients for whom light therapy is prescribed\n6. Patients able to understand French.\n7. Patients able to sign informed consent.\n\nExclusion Criteria:\n\n1. Patients with a DSM-5 diagnosis of schizophrenia, suffering from paranoid or delusional disorders, any other psychotic features or other nonstabilized mental disorders\n2. Patients with other antidepressant strategies than LT or mood stabiliser initiated in the month prior to inclusion\n3. Patients with a therapeutic resistance of current MDE (lack of response to ≥2 antidepressants of 2 different classes at therapeutic doses for \\>6 weeks)\n4. Patients with a LT used in the last 1 month\n5. Patient with ophtalmic pathologies (cataract, glaucoma, age-related macular degeneration, severe myopia \\> 6D, etc.) or diseases affecting the retina (retinitis pigmentosa, diabetes, herpes, hereditary retinal disorders etc.).\n6. Patient with photosensitive epilepsy\n7. Patients with a C-SSRS score ≥ 4\n8. For the MRI group, patient presenting one or several MRI contrindications\n9. Shiftwork or self-imposed irregular sleep schedule within the last months\n10. Travel acrosss 2 time-zones during the last month prior to participation\n11. Pregnant or breastfeeding women\n12. Subject under guardianship or deprived of liberty\n13. Participation ton another interventional study\n\nHealthy volonteers :\n\nInclusion criteria :\n\n1. Adults between 18 and 65\n2. Without any significant psychiatric history or current psychotropic medication\n3. Able to understand French\n4. Able to sign informed consent\n\nExclusion criteria :\n\n1. Contra-indications to MRI (claustrophobia, metallic or material implants)\n2. History of severe head injury\n3. Pregnancy and breastfeeding woman\n4. Inability to understand information about the study\n5. Persons deprived of their liberty by judicial or administrative decision\n6. Adult subject under legal protection or unable to consent",true,{"count":106,"type":20},173,[23],"Major depressive episode (MDE) are severe and common psychiatric disorders that affect up to 20% of the general population. MDE cause a decrease in psychosocial functioning, quality of life, and is associated with a high rate of suicides. They will be the leading cause of disability by 2030 according to the World Health Organization. The international effort carried out to identify biomarkers of MDE has been hampered by the heterogenous nature of MDE (unipolar, bipolar, seasonal, non-seasonal) and their heterogeneous response to treatment. Response rate to antidepressant drugs is only 40 to 50%, leading to the use of drug combinations and development of alternative therapeutics such as light therapy (LT). It was demonstrated that LT, as a first line treatment of MDE with and without seasonal pattern (± SP), has comparable efficacy to antidepressants. LT has the advantage of being also effective in improving both sleep, alertness and circadian rhythms, which may be altered in depression, contrary to antidepressant drugs that target mainly mood. Further research is warranted to determine the most efficient lighting parameters to use depending on depression characteristics, as well as to identify signature biomarkers of response. Besides, no studies have directly evaluated both subjective and objective biomarkers of sleep, wake, biological rhythms, and light signalling pathways and activation in patients with MDE ± SP. The main objective of the research will be to identify the signature of response to LT examining the correlation between the measures of biological and clinical parameters before LT and their evolution at the end of the procedure, and the therapeutic response.\n\nThe primary endpoint of the study will be the therapeutic response to LT measured by the difference of MADRS score between Visit 1 and Visit 4 (end of the therapeutic protocol). Therapeutic response to LT considered as a success will be defined as at least a 50% reduction of MADRS score between the two visits.",[29],[111,112,113],"major depressive episode","light therapy","seasonal pattern","NOT_YET_RECRUITING","2026-03-05",{"date":117,"type":40},"2026-03-10",{"date":119,"type":20},"2026-03-01",{"date":121,"type":20},"2029-05-01",{"name":123,"class":47},"Assistance Publique - Hôpitaux de Paris",{"id":125,"slug":4,"hasResults":10,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":129,"enrollmentInfo":130,"targetDuration":132,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":141,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":48},"100399417","NCT04480918","University of Iowa Interventional Psychiatry Service Patient Registry","INCLUSION CRITERIA:\n\n1. 18-99 years of age\n2. English-speaker with a level of understanding sufficient to agree to clinical treatment with a treatment modality offered by the Interventional Psychiatry Service, all required research procedures, and sign an informed consent document\n3. Clinical diagnosis of a major depressive episode in the context of major depressive disorder or bipolar disorder or treatment-resistant OCD evaluated by a provider on the Interventional Psychiatry Service and felt to be an appropriate candidate for clinical treatment with a treatment modality offered by the Interventional Psychiatry Service.\n\nEXCLUSION CRITERIA:\n\n1. Age less than 18 years\n2. A primary neuropsychiatric diagnosis that is not either major depressive disorder or bipolar disorder\n3. Serious, unstable medical conditions\u002Fproblems including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease, e.g. uncontrolled asthma, uncontrolled hyper\u002Fhypothyroidism or active cancer.\n4. Involuntary commitment to psychiatry inpatient units\n5. If patients have one or more of the following MRI Exclusion criteria, they will not be able to participate in those aspects of this study:\n\n   1. The presence of an implanted device including pacemaker, coronary stent, defibrillator, or neurostimulation device that is not MRI-compatible\n   2. The presence of ferromagnetic objects in the body, i.e. bullets, shrapnel, and\u002For metal slivers\n   3. Clinically-significant claustrophobia\n   4. Clinically-significant hearing loss\n   5. Pregnant or nursing women or women of child bearing potential not using at least one medically accepted means of contraception (to include oral, injectable, or implant birth control, condom or diaphragm with spermicide, intrauterine devices (IUD), tubal ligation, abstinence, or partner with vasectomy)\n   6. The presence of any medical illness likely to alter brain morphology and\u002For physiology (e.g., hypertension, diabetes) even if controlled by medications","99 Years",{"count":131,"type":20},1000,"2 Months","OBSERVATIONAL","The purpose of this study is to examine the effects of interventional\u002Fprocedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD). These treatments include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), racemic ketamine infusion and intranasal esketamine insufflation. The investigators will obtain various indicators, or biomarkers, of a depressed individuals' state before, during, and\u002For after these treatments. Such biomarkers include neurobehavioral testing, neuroimaging, electroencephalography, cognitive testing, vocal recordings, epi\u002Fgenetic testing, and autonomic nervous system measures (i.e. \"fight-or-flight\" response). The results obtained from this study may provide novel antidepressant treatment response biomarkers, with the future goal of targeting a given treatment to an individual patient (\"personalized medicine\").",[136,29,137,28,138,139,140],"Treatment Resistant Depression","Major Depression","Bipolar Disorder","Bipolar Depression","Obsessive-Compulsive Disorder",[142,143,144,145],"Electroconvulsive Therapy","Transcranial Magnetic Stimulation","Ketamine","Esketamine","2026-02-27",{"date":148,"type":40},"2026-03-03",{"date":150,"type":40},"2020-11-02",{"date":152,"type":20},"2050-08",{"name":154,"class":47},"Mark Niciu",{"id":156,"slug":4,"hasResults":10,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":104,"sex":15,"minAge":55,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":48},"100522726","NCT06086366","Presynaptic Imaging in Major Depressive Episodes After COVID-19","PCOV","Inclusion Criteria:\n\n* New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See \"Positive COVID-19 diagnosis\" listed after inclusion\u002Fexclusion criteria for a description of how this is determined.\n* Age 18 to 75.\n* Good general physical health with no active medical conditions based on self-report (except migraine or PASC).\n\nExclusion Criteria:\n\n* Use of antidepressants in the previous month (6 weeks for fluoxetine).\n* Use of stimulant medication affecting dopamine release in the previous month\n* Use of antipsychotics in the previous month\n* History of neurological disease (except migraine, and PASC) based on self-report\n* Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report\n* Presence of cigarette smoking in the past two months, based on self-report\n* Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)\n* Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)\n* Positive urine drug or cotinine screen at any timepoint during the study\n* History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)\n* Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan)\n* Breastfeeding (for females)\n* Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report\n* Claustrophobia, based on self-report\n* Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns)\n* Presence of metal implant, object or electrical devices that are contraindicated for MRI, based on self-report\n* Severe allergic reaction to alcohol","75 Years",{"count":163,"type":20},90,"The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.",[166,28,29],"Long COVID",[168,166,28,29,169,170],"PET","Anhedonia","Dopamine Neuron Loss","2026-02-09",{"date":173,"type":40},"2026-02-11",{"date":175,"type":40},"2023-08-22",{"date":177,"type":20},"2028-09-10",{"name":179,"class":47},"Centre for Addiction and Mental Health",{"id":181,"slug":4,"hasResults":10,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":206},"100613697","NCT07269964","At-Home tDCS as Maintenance Therapy","At-home tDCS as Maintenance Therapy Following Successful Treatment With rTMS, ECT, and Esketamine - A Pilot Study","MaintenanceDC","Inclusion Criteria:\n\n* Adults (≥18 years).\n* Diagnosis according to ICD-10: recurrent depressive disorder, severe depressive disorder, schizoaffective disorder (depressive episode) or bipolar affective disorder (depressive episode).\n* Clear indication for maintenance therapy after successful acute treatment (esketamine, rTMS, or ECT) with remission\u002Fimprovement of symptoms.\n* Capacity to provide informed consent, confirmed in a physician-led consent discussion.\n\nExclusion Criteria:\n\n* Currently in the acute treatment phase of an affective disorder and non-response to previous treatments.\n* Currently clinically relevant Axis II disorders.\n* Suicidal risk, including suicidal ideation.\n* Contraindications for tDCS: e.g., skin disease at electrode sites, cochlear implants.\n* Neurological, somatic, or psychiatric comorbidities that could compromise validity or safety.",{"count":78,"type":20},[23],"The primary purpuse of this pilot study is to find out whether a home-based transcranial direct current stimulation (tDCS) program is feasible and well tolerated as maintenance therapy and whether there are early signs that it helps maintain the clinical clinical benefits achieved during successful acute inpatient treatment.\n\nParticipant population:\n\nAdults (18+) with depressive disorder who had already improved\u002Fstabilized after acute treatment at our clinic (esketamine, repetitive transcranial magnetic stimulation , or electroconvulsive therapy).\n\nMain questions:\n\nFeasibility: Do participants reliably complete the home program and stay in the study?\n\nPreliminary effectiveness: Do improvements of depressive symptoms hold up over the 4-week treatment and 2-week follow-up (based on self-report and clinician-rated scales)?\n\nParticipants receive standardized instruction from trained staff and a portable tDCS device (with cap and small sponge electrodes) and complete 20 home sessions over 4 weeks (5 per week), each 30 minutes at a very low current (2 mA); the device gently ramps current up\u002Fdown for comfort.\n\nDuring treatment, participants use a smartphone app with step-by-step guidance and reminders; sessions are automatically logged. They will also fill out short weekly self-rating questionnaires and join brief phone check-ins every 2 weeks.\n\nWhere:\n\nDepartment and Outpatient Clinic of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich\n\nSafety \\& data privacy:\n\nThe device monitors electrode contact and pauses automatically if contact is poor. Typical sensations can include mild tingling or redness. The app stores anonymized session data so the care team can track progress; no personal data are exchanged between the app and the stimulator, and access is via a secure clinical portal.",[27,191,29],"Severe Depression",[193,62,194,195,196],"Non Invasive Brain Stimulation (NIBS)","at-home treatment","tdcs at home","transcranial direct current stimulation","2025-11-25",{"date":199,"type":40},"2025-12-08",{"date":201,"type":40},"2024-10-01",{"date":203,"type":20},"2026-11-29",{"name":205,"class":47},"Technical University of Munich",2,{"id":208,"slug":4,"hasResults":10,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":214,"targetDuration":4,"studyType":21,"phases":216,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},"100555178","NCT06508710","Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients","Early Efficacy of Ketamine Compared With Placebo as Adjunctive Therapy With Venlafaxine in Severely Unipolar Depressed Inpatients","MOODBOOSTER","Inclusion Criteria:\n\n* Current MDE in the context of unipolar major depressive disorder (DSM-5 criteria), hospitalized (open care) for this episode, with a minimum HDRS score of 24 and in the context of an indication for the introduction of venlafaxine treatment.\n* Patient aged between 18 and 65.\n* Signed free and informed consent\n* Membership of a social security scheme\n* For women of childbearing age, effective contraception throughout study participation.\\* (\\*Combined hormonal contraception (containing estrogen and progestin) associated with ovulation inhibition: (oral, intravaginal, transdermal), Progestin-only hormonal contraception associated with ovulation inhibition: (oral, injectable, implantable), Intrauterine device (IUD), Hormonal intrauterine system (IUS), Bilateral tubal occlusion, Vasectomized partner, Sexual abstinence.)\n\nExclusion Criteria:\n\n* Criteria relating to associated pathologies entailing particular risks: pharmaco-resistant CDE (failure of at least two properly conducted treatments with two different antidepressant treatment classes), CDE with psychotic features, psychotic disorder, bipolar disorder, current (\\\u003C1 month) substance use disorder (excluding tobacco).\n* Liver impairment (AST and\u002For ALT \\> 3 ULN, PAL and\u002For GGT and\u002For bilirubin \\> 2 ULN).\n* Severe renal insufficiency (GFR \\\u003C30ml\u002Fmin with Cockcroft's formula).\n* Bradycardia less than 55 beats per minute.\n* Contraindication to ketamine : Hypersensitivity to active substance or excipients, comatose state, central nervous system (CNS) depression, Parkinson's disease, Lewy body dementia, progressive supranuclear palsy, known prolongation of the QTc interval (\\>450ms for men and \\>470ms for women) or congenital long QT syndrome, recent acute myocardial infarction, uncompensated heart failure, history of ventricular arrhythmias or torsades de pointes, uncorrected hypokalemia (K+ \\\u003C 3. 5 mmol\u002Fl), epilepsy, uncontrolled hypertension, porphyria, history of stroke (CVA), intracranial hypertension.\n* Contraindication to venlafaxine (hypersensitivity to venlafaxine or excipients, are hereditary conditions of fructose intolerance, glucose-galactose malabsorption syndrome, or sucrase-isomaltase deficiency, unstable hypertension, no indication for venlafaxine treatment in clinician's opinion due to ineffectiveness or tolerability of previous venlafaxine treatment).\n* Current or previous treatment with venlafaxine or ketamine in the month prior to study inclusion.\n* Need to maintain another antidepressant, MAOI, Millepertuis or benzodiazepines (cyamemazine is permitted). Or potential drug interactions in case of recent cessation of these treatments (based on the Summary of Product Characteristics (SmPC) of the respective medication(s) and their half-life).\n* Any other unspecified reason (clinically significant illness or anomaly) which, in the opinion of the investigator or the sponsor, could compromise the safety of the participant.\n* Pregnant or breast-feeding patients (women of childbearing potential must have a negative urine or blood test for human chorionic gonadotropin prior to trial entry). Planned pregnancy within three months of enrolment\n* Adult under guardianship, curatorship or safeguard of justice\n* Participating in other interventional research involving the human body or within the exclusion period following previous research involving the human body, if applicable.\n* Social insurance\n\nAdditional criteria for inclusion in the ancillary study :\n\n\\- Contraindications to \\[11C\\]UCB-J PET-MRI\n\n1. Absolute contraindications: Pacemaker or neurosensorial stimulator or implantable defibrillator; clip on a brain aneurysm or vascular malformation; intraocular or intracerebral ferromagnetic foreign body; prostheses or objects or mobile ferromagnetic metal fragments; cochlear implants; peripheral stimulator; neurosurgical ventriculoperitoneal shunt valves; automated injection device such as insulin pump, glucose sensor; permanent eyelid or lip makeup; non-removable piercing; claustrophobia.\n2. Relative contraindications: Dental prostheses and orthodontic material; certain intrauterine devices; certain tattoos; certain transdermal patch implants; certain metal implants far from the examined area. (The investigator physician and\u002For radiology operator will always conduct a precise questionnaire before the examination to ensure perfect safety and absence of MRI danger)",{"count":215,"type":20},60,[217],"PHASE3","Unipolar major depressive disorder is the leading cause of disability worldwide. The most commonly used treatments for major depressive episodes (MDE) are antidepressant medications. However, they have limited efficacy and their onset of action is long, ranging between 2 to 6 weeks. During this period, hospitalization can become necessary, especially for severe MDE. It is crucial to improve the early effectiveness of treatments for these patients in order to alleviate their suffering, limit complications (suicidal risk), and reduce hospitalization durations (approximately 1000 euros per day). The efficacy of intravenous ketamine has been demonstrated in pharmaco-resistant depression but remains to be proven in non-pharmaco-resistant severe MDE. Additionally, PET imaging using \\[11C\\]UCB-J, which allows the in vivo study of synaptic density in the human brain, has shown significant decreases in synaptic density in unipolar patients with severe MDE. Furthermore, a single ketamine infusion was found to enhance synaptogenesis",[29],[221,222,223],"depression","ketamine","synaptogenesis","2025-09-01",{"date":226,"type":40},"2025-09-03",{"date":228,"type":40},"2024-10-20",{"date":230,"type":20},"2026-04",{"name":123,"class":47},4,{"id":234,"slug":4,"hasResults":10,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":239,"targetDuration":4,"studyType":21,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":48},"100563684","NCT06619366","The Impact of Coach-guided Risk Communication on the Risk of Major Depression","The Impact of Coach-guided Risk Communication on the Risk of Major Depression: A Randomized Controlled Trial","Inclusion Criteria:\n\n* no MDE at baseline, or full remission for 2 months for those who had a past MDE (see below the question).\n* Aged 18 and 65 years.\n* At high risk of MDE based on the depression risk calculators (predicted risk of 6.5%+ for males and 11.2%+ for females), which represent the top two deciles of male and female populations in Canada.\n* Agreement to be contacted for follow-up assessments, and\n* no language barriers to English or French\n\nExclusion Criteria:\n\nindividuals who\n\n* cannot provide informed consent,\n* do not agree to be followed,\n* cannot communicate in English and French, or\n* report suicide behaviors (score \\>0 on item 9 of the Patient Health Questionnaire (PHQ-9)).",{"count":131,"type":20},[23],"Depression is a highly prevalent and disabling mental health problem. One way of preventing depression is to stop it before it happens through effective self-management. Working with potential users, a coach-guided, personalized depression risk communication tool (PDRC) was developed for sharing information about individualized depression risk, risk profile (risk factors present), potential risk reduction and evidence-based self-help strategies. It is anticipate that the PDRC will greatly motivate users to actively engage in self-help and help seeking, leading to a reduced risk of depression. The proposed study will recruit 500 male and 500 female adults who are at high risk of having depression across Canada, and randomly allocate them into the intervention and control groups. Participants will be followed for 12 months. The data of the trial will allow us to answer the questions: (1) Can the coach-guided PDRC reduce the risk of depression? (2) Does the intervention motivate people to actively engage in evidence-based self-help and help-seeking behaviors? (3) For whom the intervention works best? and (4) what are the costs and potential savings associated with the intervention? If successful, this project will offer a novel and effective tool for early prevention of major depression in the Canadian general population, help us understand how it works and the cost-effectiveness of implementing such a tool in the community from the economic perspective.",[29,243,244],"Risk Reduction","Self Efficacy",[111,246,247,248],"risk communication","coach-guided","self-help","2025-08-26",{"date":251,"type":40},"2025-09-02",{"date":253,"type":40},"2025-02-10",{"date":255,"type":20},"2029-10",{"name":257,"class":47},"Dalhousie University",{"id":259,"slug":4,"hasResults":10,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":266,"briefSummary":267,"conditions":268,"keywords":270,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100335333","NCT03646058","Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode","BUPRIS","Inclusion Criteria:\n\n* The patient has been correctly informed.\n* The patient must have given his\u002Fher informed and signed the consent form.\n* The patient must be insured or beneficiary of a health insurance plan.\n* The patient is at least 18 years old and 65 years old at the most.\n* The patient is hospitalized or followed in consultation.\n* The patient has a current major depressive episode without psychotic features according to the criteria of the \"Diagnostic and Statistical Manual of Mental Disorders\"\n* The patient has a score \\> 20 of the \"Montgomery-Asberg Depression Rating Scale\".\n* The patient has a current Scale for Suicidal Ideation (SSI) score \\> 8.\n\nExclusion Criteria:\n\n* The patient is participating in another interventional trial;\n* The patient is in an exclusion period determined by a previous study;\n* The patient is under judicial protection, or is an adult under guardianship;\n* The patient is under compulsory admission;\n* The patient refuses to sign the consent;\n* it is impossible to correctly inform the patient.\n* The patient is pregnant or breastfeeding.\n* The patient suffers from schizophrenia;\n* The patient suffered from moderate to severe alcohol use disorder or substance use disorder (except tobacco and caffeine) over the last 12 months according to DSM-5 criteria ;\n* The patient currently suffers from severe and\u002For unstable medical condition (including severe respiratory or hepatic insufficiency) or a painful medical condition;\n* The patient has a current known sleep apnea.\n* The patient currently takes analgesic treatment (including Nonsteroidal anti-inflammatory drug and paracetamol);\n* The patient currently takes central nervous depressant drugs at sedative doses (based on the investigator's assessment), including benzodiazepines, antihistamines, and sedative antipsychotics;\n* The patient currently takes major CYP3A4 Inhibitors and inducers;\n* The patient currently takes has received Electroconvulsivotherapy over the last 3 months.",{"count":265,"type":20},180,[217],"This study aims at investigating if adjunctive buprenorphine at low dose to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode, and at determining the most effective dose.",[269,29],"Suicidal Ideation",[271,272,26,273,274,275],"Treatment","Suicidal ideas","Buprenorphine","Opioid agonist","Mental pain","2025-08-19",{"date":278,"type":40},"2025-08-21",{"date":280,"type":40},"2021-10-10",{"date":282,"type":20},"2027-01",{"name":284,"class":47},"Centre Hospitalier Universitaire de Nīmes",9,{"id":287,"slug":4,"hasResults":10,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":21,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":48},"100514066","NCT05973643","Metabolomics During ElectroConvulsivoTherapy","Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode","METECT","Inclusion Criteria:\n\n* Major depressive episode according to DSM-5 criteria\n* Diagnosis of major depressive disorder or bipolar disorder\n* MADRS score \\>22\n* having given written, free and informed consent\n* without protective measures\n* resistance criterion defined as failure of 2 antidepressants at an effective dose for a minimum of 6 weeks\n* current major depressive episode according to DSM-5 criteria with indication of treatment by ECT cure\n\nExclusion Criteria - Cannot be included in the study, people:\n\n* whose consent is not admissible or who refuse to participate in the study\n* deprived of liberty by judicial or administrative decision\n* For which there is a particular risk contraindicating the cure of ECT\n* Suffering from schizophrenia spectrum disorders or persistent delusional disorder as described by DSM-5 Criterion D for Major Depressive Disorder\n* suffering from neurological disorders (such as patients suffering from multiple sclerosis, epilepsy, encephalitis, etc.) and\u002For neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease or related diseases, etc.) as described by criterion C of the major depressive disorder listed in the DSM-5\n* suffering from an acute or chronic systemic inflammatory disease requiring specific treatment with immunomodulators or suppressors. As well as any recurrent inflammatory disease requiring specific management, and which may lead to a differential diagnosis of the characterized depressive episode as described by criterion C listed in the DSM-5",{"count":294,"type":20},50,[23],"Investigators will measure the variation of blood Metabolome through 1H NMR at several time points during the course of electroconvulsivetherapy in patients with a major depressive episode. Patients with a major depressive disorder or a bipolar disorder and a current major depressive episode will be included in this study. Investigators hypothesized that Metabolome could be a source to predict response during ECT and to help understanding underlying biological mechanisms.",[29,298],"ECT",[300,142,137],"1HNMR","2025-07-23",{"date":303,"type":40},"2025-07-24",{"date":305,"type":40},"2024-03-11",{"date":307,"type":20},"2026-10-15",{"name":309,"class":47},"Hôpital le Vinatier",{"id":311,"slug":4,"hasResults":10,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":315,"targetDuration":4,"studyType":21,"phases":317,"briefSummary":318,"conditions":319,"keywords":322,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":48},"100372557","NCT04130958","Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics","Inclusion Criteria:\n\n* 18-65 years of age\n* Diagnosed with BPD or MDE\n* Chief complaint of suicidal thoughts and behaviors\n\nExclusion Criteria:\n\n* Neurological conditions with known structural brain lesion\n* Prior neurosurgical procedure\n* Metal in the body that is ferromagnetic or metal injury to the eyes\n* Epilepsy\n* Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt\n* Psychopathology not appropriate for the treatment (e.g., manic episode or psychosis)\n* Current alcohol dependence or active symptoms of non-alcohol psychoactive substance use withdrawal, as indicated by self-report\n* Inability to meet the safety criteria for MRI scanning according to the protocols of the MGH Department of Radiology\n* Current pregnancy",{"count":316,"type":20},80,[23],"This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).",[29,320,321],"Borderline Personality Disorder","Suicide",[143,323],"Intermittent Theta Burst","2025-06-10",{"date":326,"type":40},"2025-06-12",{"date":328,"type":40},"2023-11-01",{"date":330,"type":20},"2026-04-30",{"name":332,"class":47},"Massachusetts General Hospital",{"id":334,"slug":4,"hasResults":10,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":21,"phases":341,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":48},"100441466","NCT05028738","Patient-oriented Randomized Pragmatic Feasibility Trial with RTMS in Depression and Anxiety","PORT","Inclusion Criteria:\n\n1. are outpatients;\n2. are voluntary and competent to consent to treatment;\n3. are ≥ 18 years;\n4. have a score ≥ 26 on the IDS-30-SR;\n5. have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;\n6. able to adhere to the treatment schedule;\n7. pass the TMS adult safety screening (TASS) questionnaire\n\nExclusion Criteria:\n\n1. have active suicidal intent;\n2. are pregnant;\n3. have a lifetime diagnosis of schizophrenia, bipolar disorder type I, schizophreniform, schizoaffective disorder or presence of psychotic symptoms within last 3 months;\n4. have a concomitant major unstable medical illness;\n5. have any significant form of dementia or any history of epilepsy;\n6. have any intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;\n7. If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study;\n8. If they are taking psychotropic medication, be on a stable dose for 4 weeks before starting treatment, and no initiation of new regular psychotropic medication;\n9. have a clinically significant laboratory abnormality, in the opinion of the one of the principal investigators;\n10. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview).",{"count":340,"type":20},100,[23],"This trial compares intermittent theta-burst stimulation (iTBS) to low frequency repetitive transcranial magnetic stimulation (LFR) in regards to depression and anxiety outcomes in 100 patients with treatment resistant depression (TRD).",[29,28],[345,346,347,348,143,349],"Pragmatic","Patient-oriented research","TMS","Treatment-resistant depression","rTMS","2024-12-18",{"date":352,"type":40},"2024-12-20",{"date":354,"type":40},"2021-10-11",{"date":356,"type":20},"2025-08",{"name":358,"class":47},"University of British Columbia",{"id":360,"slug":4,"hasResults":10,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":367,"conditions":368,"keywords":370,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":48},"100572347","NCT06732089","Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot Study","Determining the Feasibility of Digital Interventions for Adults with Treatment-Resistant Depression","Inclusion Criteria:\n\n* Adults (aged 18+) who are capable of giving informed consent\n* Patients meeting diagnostic criteria for major depressive disorder (MDD) without psychotic symptoms according to the DSM-5\n* Currently experiencing a major depressive episode (MDE)\n* Montgomery-Asperg Depression Rating Scale (MADRS) score greater than 20 at screening\n* Patients meeting criteria for treatment-resistant depression (TRD): failure of 2 or more adequate trials of antidepressant therapy of adequate dose and duration during the current episode\n* Enrollment in one of the treatment modalities (rTMS, IVK, or ECT) at the Interventional Psychiatry Program at St. Michael's Hospital, Unity Health Toronto\n* Ownership of a smartphone (for participants using wearable devices)\n\nExclusion Criteria:\n\n* Individuals without Internet access (required to access study platforms)\n* Medication changes, aside from the treatment received through the IPP, one month (28 days) before screening, or during the entire duration of treatment (variable based on treatment arm)\n* Participants who do not speak English fluently enough to successfully communicate study information, answer questions accurately, and\u002For obtain informed consent",{"count":366,"type":20},200,"The goal of this observational study is to learn about remote mental health monitoring technology for adults with treatment-resistant depression. The main question it aims to answer is: are digital mental health monitoring tools (an electronic data capture platform and wearable device (e.g., smartwatch or smart-ring)) feasible to implement alongside clinical treatment for depression? The secondary aim of this study is to inform preliminary clinical parameters for larger, definitive studies.\n\nParticipants receiving neuropsychiatric treatment (repetitive transcranial magnetic stimulation, intravenous ketamine, or electroconvulsive therapy) as part of their regular medical care for treatment-resistant depression in the Interventional Psychiatry Program will have their clinical assessment data entered into a digital platform and will wear an accessory-based wearable device for the duration of treatment.",[369,29,85],"Major Depressive Disorder (MDD)",[371,372,373,374,375,376,377,378],"pilot study","digital health monitoring","wearable device","remote measurement-based care","treatment-resistant depression","observational study","feasibility study","electronic data capture","2024-12-09",{"date":381,"type":40},"2024-12-13",{"date":383,"type":20},"2024-12-16",{"date":385,"type":20},"2026-12",{"name":387,"class":47},"Unity Health Toronto",{"id":389,"slug":4,"hasResults":10,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":10,"sex":15,"minAge":395,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":21,"phases":398,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":48},"100556310","NCT06523439","Accelerated Intermittent Theta Burst in Treatment-Naive Adolescents","Investigating a Truncated Version of SAINT in Treatment-Naive Adolescents With Depression: An Open-Label Acceptability Trial","SAINT-KID","Inclusion Criteria:\n\n1. Male or Female, between the ages of 14 and 19 at the time of screening.\n2. Able to read, understand, and provide written, dated assent and\u002For consent prior to screening. Proficiency in English sufficient to complete questionnaires and follow instructions during aiTBS interventions. Stated willingness to comply with all study procedures, including availability for the duration of the study, and to communicate with study personnel about adverse events and other clinically important information.\n3. Diagnosed with Major Depressive Disorder (MDD) with a current Major Depressive Episode (MDE), according to the criteria defined in the Diagnosis and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5).\n4. No prior major depressive episodes (MDEs) as determined by MINI-KID\n5. HAMD-17 score of ≥20 at screening (Visit 1).\n6. Treatment-naive as determined by the ATHF (no adequate antidepressant trials prior to screening defined as fewer than 4 weeks of antidepressant medication and fewer than 8 psychotherapy sessions in lifetime; willingness to taper medications and stop psychotherapy if recently started and within the window defined above.)\n7. TMS naive.\n8. Access to ongoing psychiatric care before and after completion of the study.\n9. In good general health, as evidenced by medical history.\n10. Agreement to adhere to Lifestyle Considerations throughout study duration.\n\nExclusion Criteria:\n\n1. Pregnancy\n2. High-risk for suicide or active suicidal ideation (Suicidal Ideation Questionnaire- Junior \\[SIQ-JR\\] ≥ 31).\n3. The presence or diagnosis of prominent anxiety disorder, or dysthymia (\\>3 on SAPAS; \\>10 on GAD-7)\n4. Current severe insomnia (must sleep a minimum of 5 hours each night before stimulation)\n5. Current mania or psychosis\n6. Bipolar Affective Disorder and\u002For primary psychotic disorders.\n7. Autism Spectrum disorder or Intellectual Disability\n8. A diagnosis of obsessive-compulsive disorder (OCD)\n9. Current moderate or severe substance use disorder or demonstrating signs of acute substance withdrawal.\n10. Urine screening test positive for illicit substances.\n11. Any history of ECT (greater than 8 sessions) without meeting responder criteria\n12. Recent (during the current depressive episode) or concurrent use of a rapid acting antidepressant agent (i.e., ketamine or a course of ECT).\n13. History of significant neurologic disease, including dementia, Parkinson's or Huntington's disease, brain tumor, unexpected seizure\u002Fepilepsy disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma.\n14. Untreated or insufficiently treated endocrine disorder.\n15. Contraindications to receiving rTMS (e.g., metal in head, history of seizure, known brain lesion)\n16. Contraindications to MRI (ferromagnetic metal in their body).\n17. Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.\n18. Depth-adjusted aiTBS treatment dose \\> 65% maximum stimulator output (MSO)\n19. Treatment with another investigational drug or other intervention within the study period.\n20. Any other condition deemed by the PI to interfere with the study or increase risk to the participant.","14 Years","19 Years",{"count":19,"type":20},[23],"This is a single-site open-label clinical trial of the Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) protocol. The goal of this clinical trial is to learn if a new form of transcranial magnetic stimulation (TMS)-known generally as accelerated intermittent theta burst stimulation (aiTBS) and specifically as SAINT®-is effective as a first-line therapy in treating adolescents aged 14-19 years-old in their first episode of depression who have not undergone a full course of depression treatment prior to starting the trial and who remain antidepressant-free throughout the trial.\n\nThe main questions this trial aims to answer are:\n\n* Does SAINT® relieve symptoms of depression as a first-line therapy in adolescents?\n* Is SAINT® a feasible option as a first-line treatment for adolescent depression?\n\nResearchers will measure the depression symptoms in adolescent participants before and after SAINT®. Parents of the adolescent participant will also participate in the study providing information about their experience and preference for TMS as a first-line treatment.\n\nAdolescent participants will:\n\n* Remain antidepressant-free throughout the study period of 6-7 weeks.\n* Receive an MRI of their head for precision targeting\n* Receive 5 days of aiTBS (SAINT®)",[28,401,26,29],"Depression in Adolescence",[403,404,143,405,406,347,407],"Stanford Accelerated Intelligent Neuromodulation Therapy","SAINT","Accelerated Theta Burst Stimulation","Accelerated Intermittent Theta Burst Stimulation","TMS in Adolescents","2024-12-06",{"date":410,"type":40},"2024-12-12",{"date":412,"type":20},"2025-01",{"date":414,"type":20},"2026-09",{"name":416,"class":47},"University of Texas at Austin",{"id":418,"slug":4,"hasResults":10,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":104,"sex":15,"minAge":55,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":426,"conditions":427,"keywords":430,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":447,"locationsCount":48},"100522286","NCT06080646","Reward Processing and Depressive Subtypes: Identifying Neural Biotypes","Reward Processing and Depressive Subtypes: Identifying Neural Biotypes Related to Suicide Risk, Resilience, and Treatment Response","* Our studies require some in-person visits to our research lab, located at 42nd Ave and Clement St in San Francisco.\n* Because this study includes an MRI, part of the screening process will be to ensure you don't have any metal in your body, you do not have head or neck tattoos, and you are comfortable inside the MRI scanner.\n\nInclusion Criteria:\n\n* 18-70 years with a diagnosis of major depressive disorder (MDD) for MDD group, or without for unaffected comparison (UC) group\n* Negative metal screen for MRI safety\n* Normal (or corrected to normal) vision\n\nExclusion Criteria:\n\n* Past or present neurological problems (including seizures and head trauma resulting in neurological or cognitive symptoms)\n* Loss of consciousness (LOC) greater than 30 minutes or any LOC with neurologic symptoms\n* Major medical conditions (e.g., seizure disorders, treatment with anticonvulsant medication, endocrine disorders, significant cardiac pathology)\n* Substance dependence, within the past year, or failed urine toxicology on the day of neuroimaging sessions\n* Known claustrophobia\n* Current Pregnancy\n* IQ estimate \\\u003C 70","70 Years",{"count":425,"type":20},150,"Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception, including individual variation in symptoms, severity, and treatment response. This heterogeneity complicates understanding of depression and thwarts progress toward disease classification and treatment planning. Discovery of depression-specific biomarkers that account for neurobiological variation that presumably underlies distinct clinical manifestations is critical to this larger effort.",[26,428,28,29,429,169],"Depressive Disorder","Depressive Symptoms",[431,432,433,434,435,436,437,438,439,440],"reward","motivation","EEG","fMRI","MRI","functional MRI","amotivation","avolition","suicidality","suicide","2024-07-31",{"date":443,"type":40},"2024-08-02",{"date":445,"type":40},"2021-06-01",{"date":224,"type":20},{"name":448,"class":449},"San Francisco Veterans Affairs Medical Center","FED",{"id":451,"slug":4,"hasResults":10,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":457,"conditions":458,"keywords":459,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":48},"100505869","NCT05866991","Cohort of Patients Suffering From Major Depressive Episode With Evaluation of Sleep, Circadian Rhythms and Psychiatric Disorders","SoPsy-SoSad","Inclusion Criteria:\n\n* Individuals with depressive episode characterized according to the DSM-5 criteria regardless of the associated characteristics and comorbidities.\n* Adult and child\n* Affiliated to a social security\n\nExclusion Criteria:\n\n* don't understand or read french\n* Medical condition incompatible with administration of questionnaire\n* impossibility to give informed decision (subject in an emergency condition, etc.)",{"count":131,"type":20},"Despite international efforts to identify biomarkers of depression, none has been transferred to clinical practice, neither for diagnosis, evolution, nor therapeutic response. This led us to build a French national cohort (through the clinical and research network named SoPsy within the French biological psychiatry society (AFPBN) and sleep society (SFRMS)), to better identify markers of sleep and biological rhythms and validate more homogeneous subgroups of patients, but also to specify the manifestations and pathogeneses of depressive disorders.",[29],[26,460,461,462,463,464,465],"Biomarkers","Depressive","Disorder","Sleep","circadian rhythms","seasonal affective disorder","2024-05-15",{"date":468,"type":40},"2024-05-16",{"date":470,"type":40},"2023-02-01",{"date":472,"type":20},"2033-05-01",{"name":123,"class":47},{"id":475,"slug":4,"hasResults":10,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":10,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":480,"targetDuration":4,"studyType":21,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":491,"locationsCount":48},"100373482","NCT04142996","Comparing Uni- and Bi-lateral TBS in Major Depression","A Naturalistic Study Comparing Uni- and Bi-lateral Theta Burst Stimulation in Major Depression","Inclusion Criteria:\n\n1. voluntary and competent to consent to study,\n2. female or male aged 18 years old or older,\n3. can speak and read English and\u002For French\n4. primary and\u002For predominant diagnosis of major depressive episode without psychotic features in the current depressive episode (confirmed by a Mini-International Neuropsychiatric Interview),\n5. depressive symptoms have not improved after ≥ 1 adequate dose of antidepressant trial in the current depressive episode,\n6. moderate symptoms in the current depressive episode as indexed by a score of at least 15 at the 17-item Hamilton Rating Scale for Depression (HRSD-17),\n7. have been referred to rTMS treatment by their treating physician, and took a free and informed decision to follow this treatment,\n8. are able to adhere to treatment schedule,\n9. have received a stable psychiatric medication (including prescribed cannabis) or psychotherapy regimen for at least four weeks prior to entering the trial,\n10. have an education-adjusted score of ≥ 24 at the Mini-Mental State Evaluation (MMSE) if are aged ≥ 65.\n\nExclusion Criteria:\n\n1. current or past (\\\u003C 3 months) substance (excluding caffeine or nicotine) or alcohol abuse\u002Fdependence, as defined in the Diagnostic and Statistical Manual 5th Edition (DSM-5) criteria. Based on the DSM-5 criteria, mild cannabis or alcohol use would be permissible in the past 3 months, moderate to severe would be an exclusion\n2. current use of illegal substances or recreational cannabis\n3. have a concomitant major unstable medical or neurologic illness (e.g. uncontrolled diabetes or renal dysfunction),\n4. organic cause to the depressive symptoms (e.g. thyroid dysfunctions), determined by the referring physician\n5. acute suicidality or threat to life from self-neglect,\n6. are pregnant or breastfeeding, or thinking of becoming pregnant during course of treatment,\n7. have a specific contraindication for TMS (e.g., personal history of epilepsy or seizure, metallic head implant, pacemaker),\n8. unwilling to maintain current antidepressant regimen,\n9. are taking more than 1 mg of lorazepam or equivalent,\n10. any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study,\n11. have failed a course of electroconvulsive therapy (ECT) within the current depressive episode due to the lower likelihood of response to rTMS.If they have had failed ECT in the past, this does not exclude them",{"count":481,"type":20},256,[23],"Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS) is a very promising new treatment for major depression that allows a 15-fold reduction in duration of daily sessions. However, no large scale naturalistic study has assessed the superiority of bilateral TBS in comparison with unilateral left TBS. In fact, no TBS study thus far has included both unipolar and bipolar depression, or other psychiatric comorbidities such as anxiety. Maintenance has yet to be studied with TBS, along with an effective maintenance protocol to prevent relapse. Our study aims to explore and address these gaps.",[29],"2023-11-28",{"date":487,"type":40},"2023-12-04",{"date":489,"type":40},"2019-12-12",{"date":414,"type":20},{"name":492,"class":47},"The Royal Ottawa Mental Health Centre",""]